Mobile menu
Home » Celiac Disease Research » Drug Development » Drug Development Pipeline

Refine Pipeline

Use the filters below to refine your results

Phase

 Pre-clinical
Phase One
Phase Two
Phase Three
Available to Patients

Therapeutic Approach
Binding gluten so it’s not absorbed
Breaking down gluten using enzymes
Interrupting the immediate or delayed effects of gluten on the cells lining the intestine
Preventing the enzyme tTG from modifying gluten in the cell, which helps to reduce an abnormal immune response
Inducing immune tolerance to protect against the effects of gluten by preventing an immune reaction
Interrupting the immune reactions that occur

Status

 Active
Discontinued

Associated Websites

Drug Development Pipeline

Drug Development Pipeline

And to learn about the phases and process of drug development, download our Clinical Trials infographic.

Last updated September 19, 2024

Therapeutic Approach

Binding gluten so it’s not absorbed

Pre-Clinical
Phase One
Phase Two
Phase Three
Available
BL-7010 (BioLineRx)

END PHASE TWO
Therapeutic Approach

Breaking down gluten using enzymes

Pre-Clinical
Phase One
Phase Two
Phase Three
Available
IMGX-003/Latiglutenase (Entero Therapeutics)

END PHASE TWO
TAK-062, or Kuma062 (Takeda Pharmaceuticals)

START PHASE TWO
E40 (Nemysis)

MID PRE-CLINICAL
Therapeutic Approach

Interrupting the immediate or delayed effects of gluten on the cells lining the intestine

Pre-Clinical
Phase One
Phase Two
Phase Three
Available
Larazotide Acetate (9 Meters Biopharma)

START PHASE THREE
IMU-856 (Immunic Inc)

END PHASE ONE
Therapeutic Approach

Preventing the enzyme tTG from modifying gluten in the cell, which helps to reduce an abnormal immune response

Pre-Clinical
Phase One
Phase Two
Phase Three
Available
GSK3915393 (GSK)

START PHASE ONE
ZED 1227/TAK 227 (Zedira, Dr. Falk and Takeda)

MID PHASE TWO
Therapeutic Approach

Inducing immune tolerance to protect against the effects of gluten by preventing an immune reaction

Pre-Clinical
Phase One
Phase Two
Phase Three
Available
TAK-101 ( Takeda Pharmaceuticals)

START PHASE TWO
Nexvax2 (ImmusanT)

START PHASE TWO
Name TBD (Selecta Biosciences)

MID PRE-CLINICAL
TPM502 (Topas Therapeutics )

START PHASE TWO
KAN-101 (Anokion)

START PHASE TWO
VTP-1000 (Barinthus Biotherapeutics)

START PHASE ONE
AG017 (ActoBio Therapeutics)

END PRE-CLINICAL
ALL-001 (Allero Therapeutics )

MID PRE-CLINICAL
SQZ TAC (SQZ Biotechnologies)

MID PRE-CLINICAL
Therapeutic Approach

Interrupting the immune reactions that occur

Pre-Clinical
Phase One
Phase Two
Phase Three
Available
PRV-015 (formerly AMG 714) Non-responsive celiac disease (Amgen/Provention Bio)

MID PHASE TWO
AMG 714 Refractory celiac disease type 2 (Amgen)

END PHASE TWO
Hu-Mik-Beta 1 Refractory celiac disease (National Cancer Institute, Mayo Clinic, University of Chicago Medicine Celiac Disease Center)

END PHASE ONE
DONQ52 (Chugai Pharmaceutical Co.)

MID PHASE ONE
CALY-002 (Calypso Biotech)

MID PHASE ONE
TEV-53408 (Teva Pharmaceuticals)

START PHASE ONE
Vedolizumab (Investigator initiated in collaboration with Takeda Pharmaceuticals)

END PHASE ONE
EQ-102 (Equillium )

END PRE-CLINICAL
Guselkumab (Janssen)

START PHASE ONE
No drugs match your filter selections.

Think you may have celiac disease?

Symptoms Checklist
OUR PARTNERS